Consumers’ OTC drug choices extend beyond pain relievers, heartburn remedies and allergy formulations, Prestige Consumer Healthcare points out by noting its Dramamine motion sickness and Nix lice treatment line as sales growth leaders in its latest quarter.
The firm on 3 August announced reported revenues for its fiscal 2024 first quarter increased 0.8% to $279.3m, or 1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?